Drug Trial Radar · NCT00703755
A Randomized, Double-Blind Trial Comparing the Efficacy and Safety of Fenofibrate, Metformin, Their Combination and Placebo in Patients With Metabolic Syndrome.
Last checked: Nov 20, 2026Latest source record: Jun 25, 2008 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,288
Actual
Start
Mar 2003
Primary completion
Jun 2004
Study completion Jun 2004
Sponsor
- Lead sponsor
- Solvay PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Jun 23, 2008
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to study the effect of different combinations of fenofibrate and metformin on the cluster of metabolic syndrome (MetS) biochemical abnormalities, and to determine the dose combination allowing normalization of MetS patients.
Conditions
- Patients With Metabolic Syndrome
Interventions
Fenofibrate /MetforminDrug
fenofibrate 2 x 40 mg bid + metformin 850 mg bid (F160-M1700)
Fenofibrate /MetforminDrug
fenofibrate 2 x 40 mg bid + metformin 500 mg bid (F160-M1000)
Fenofibrate /MetforminDrug
fenofibrate 40 mg bid + metformin 850 mg bid (F80-M1700)
Fenofibrate /MetforminDrug
fenofibrate 40 mg bid + metformin 500 mg bid (F80-M1000)
Fenofibrate /MetforminDrug
fenofibrate 2 x 40 mg bid + metformin placebo (F160-M0)
Fenofibrate /MetforminDrug
fenofibrate placebo + metformin 850 mg bid (F0-M1700)
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- The percentage of normalized patients at V4 (fasting glucose < 6.1 mmol/L, TG < 1.69 mmol/L and HDL-C >= 1.03 mmol/L in males and >= 1.29 mmol/L in females)Time frame: End of study visit (V4)
Locations
101 sites in 9 countries. Site status is shown where the registry gives one.
Site 007
Chicoutimi, Canada
Site 024
Halifax, Canada
Site 004
Hamilton, Canada
Site 012
Kingston, Canada
Site 017
Longueuil, Canada
Site 009
Montague, Canada
Site 001
Montreal, Canada
Site 015
Montreal, Canada
Site 003
Québec, Canada
Site 025
Sainte-Foy, Canada
Site 026
Sainte-Foy, Canada
Site 021
Sherbrooke, Canada
Site 010
St. John's, Canada
Site 020
St. John's, Canada
Site 022
St. John's, Canada
Site 006
Ste-Foy, Canada
Site 016
Toronto, Canada
Site 005
Vancouver, Canada
Site 011
Victoria, Canada
Site 013
Calgary, Alberta, Canada
Site 019
Calgary, Alberta, Canada
Site 090
Hus, Finland
Site 091
Jakobstad, Finland
Site 095
Jyväskylä, Finland
Site 092
Mikkeli, Finland
Site 096
Närpes, Finland
Site 094
Vaasa, Finland
Site 190
Budapest, Hungary
Site 191
Budapest, Hungary
Site 193
Budapest, Hungary
Site 199
Budapest, Hungary
Site 202
Budapest, Hungary
Site 204
Budapest, Hungary
Site 203
Debrecen, Hungary
Site 200
Gyöngyös, Hungary
Site 201
Győr, Hungary
Site 198
Gyula, Hungary
Site 197
Miskolc, Hungary
Site 196
Pécs, Hungary
Site 194
Szeged, Hungary
Showing 40 of 101 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.